MedTrace Logo

Intravitreal Bevacizumab for Retinal Disorders

NCT00403026 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2006-11-23

No results posted yet for this study

Summary

Bevacizumab is an anti-VEGF agent used in approved for use in metastatic colorectal carcinoma (FDA Approved). This study analyzes the safety and efficacy of off-label Intravitreal Injection of bevacizumab (Avastin) for CNVM, Macular oedema due to diabetic retinopathy, vascular occlusion and other retinal disorders.

Conditions

  • Wet AMD
  • Macular Oedema
  • Proliferative Diabetic Retinopathy

Interventions

DRUG

Bevacizumab ( Avastin)

Sponsors & Collaborators

  • Narayana Nethralaya

    lead OTHER

Principal Investigators

  • sivakami pai, MS · Narayana Nethralaya, Bangalroe, India

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Completion
2006-11-30

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00403026 on ClinicalTrials.gov